A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors.

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Clinical Effects of ON 01910.Na in Combination With Either Irinotecan or Oxaliplatin in Patients With Hepatoma and Other Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Rigosertib (Primary) ; Irinotecan; Oxaliplatin
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 31 Dec 2011 Actual patient number is 16 as reported by ClinicalTrials.gov.
    • 13 Jul 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
    • 13 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top